{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:32:34Z","timestamp":1794270754968,"version":"4.9.0"},"reference-count":44,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["20130614"],"award-info":[{"award-number":["20130614"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Northern Territory Department of Health"},{"DOI":"10.13039\/501100006285","name":"Magnus Bergvalls Stiftelse","doi-asserted-by":"publisher","award":["2017-02138 and 2018-02566"],"award-info":[{"award-number":["2017-02138 and 2018-02566"]}],"id":[{"id":"10.13039\/501100006285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["2016fobi49958"],"award-info":[{"award-number":["2016fobi49958"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Practitioner Fellowship #1078477"],"award-info":[{"award-number":["Practitioner Fellowship #1078477"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,11,7]]},"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the benefit and risk of low-dose acetylsalicylic acid (aspirin) in patients from remote Aboriginal communities in the Northern Territory, Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study using primary care and hospital data routinely used for healthcare. Aspirin users and non-users were compared before and after controlling confounders by matching. Marginal structural models (MSM) were applied to ascertain the benefit and risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The benefit and harm of aspirin were investigated in patients aged \u226518 years from 54 remote Aboriginal communities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>None had a previous cardiovascular event or major bleeds. Patients on anticoagulants or other antiplatelets were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Aspirin at a dose of 75\u2013162 mg\/day.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Endpoints were all-cause, cardiovascular mortality and incidences of cardiovascular events and major bleeds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>8167 predominantly Aboriginal adults were included and followed between July 2009 and June 2017 (aspirin users n=1865, non-users n=6302, mean follow-up 4 years with hospitalisations 6.4 per person). Univariate analysis found material differences in demographics, prevalence of chronic diseases and outcome measures between aspirin users and non-users before matching. After matching, aspirin was significantly associated with reduced all-cause mortality (HR=0.45: 95% CI 0.34 to 0.60; p&lt;0.001), but not bleeding (HR=1.13: 95% CI 0.39 to 3.26; p=0.820). After using MSMs to eliminate the effects of confounders, loss of follow-up and time dependency of treatment, aspirin was associated with reduced all-cause mortality (HR=0.60: 95% CI 0.47 to 0.76; p&lt;0.001), independent of age (HR=1.06; p&lt;0.001), presence of diabetes (HR=1.42; p&lt;0.001), hypertension (HR=1.61; p&lt;0.001) and alcohol abuse (HR=1.81; p&lt;0.001). No association between aspirin and major bleeding was found (HR=1.14: 95% CI 0.48 to 2.73; p=0.765). Sensitivity analysis suggested these findings were unlikely to have been the result of unmeasured confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Aspirin was associated with reduced all-cause mortality. Bleeding risk was less compared with survival benefits. Aspirin should be considered for primary prevention in Aboriginal people with high cardiovascular risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-030034","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T18:28:02Z","timestamp":1578421682000},"page":"e030034","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["All-cause mortality following low-dose aspirin treatment for patients with high cardiovascular risk in remote Australian Aboriginal communities: an observational study"],"prefix":"10.1136","volume":"10","author":[{"given":"Yuejen","family":"Zhao","sequence":"first","affiliation":[{"name":"Health Gains Planning, Department of Health, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanakamani","family":"Jeyaraman","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Royal Darwin Hospital, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Burgess","sequence":"additional","affiliation":[{"name":"NT Medical School, Flinders University, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Connors","sequence":"additional","affiliation":[{"name":"Top End Health Services, NT Department of Health, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Guthridge","sequence":"additional","affiliation":[{"name":"Menzies School of Health Research, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Maple-Brown","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Royal Darwin Hospital, Darwin, Northern Territory, Australia"},{"name":"Menzies School of Health Research, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-6987","authenticated-orcid":false,"given":"Henrik","family":"Falhammar","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Royal Darwin Hospital, Darwin, Northern Territory, Australia"},{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"2025121411224285000_10.1.e030034.1","unstructured":"Australian Bureau of Statistics . 2016 Census Community Profiles. Canberra: ABS, 2018. Available: http:\/\/www.censusdata.abs.gov.au\/census_services\/getproduct\/census\/2016\/communityprofile\/7?opendocument [Accessed 20 Dec 2018]."},{"key":"2025121411224285000_10.1.e030034.2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12170-011-0165-5","article-title":"The combined burden of diabetes and cardiovascular disease in Indigenous Australians","volume":"5","author":"Maple-Brown","year":"2011","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"2025121411224285000_10.1.e030034.3","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/imj.13123","article-title":"Management of diabetes in Indigenous communities: lessons from the Australian Aboriginal population","volume":"46","author":"Nguyen","year":"2016","journal-title":"Intern Med J"},{"key":"2025121411224285000_10.1.e030034.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015033","article-title":"Cost-Effectiveness of stroke care in Aboriginal and non-Aboriginal patients: an observational cohort study in the Northern Territory of Australia","volume":"7","author":"Zhao","year":"2017","journal-title":"BMJ Open"},{"key":"2025121411224285000_10.1.e030034.5","unstructured":"Baker Heart & Diabetes Institute . The dark heart of type 2 diabetes. Melbourne: Baker Heart & Diabetes Institute, 2018."},{"key":"2025121411224285000_10.1.e030034.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.02.008"},{"key":"2025121411224285000_10.1.e030034.7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.diabres.2012.12.017","article-title":"Similarities and differences in cardiometabolic risk factors among remote Aboriginal Australian and Canadian cohorts","volume":"100","author":"Maple-Brown","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"2025121411224285000_10.1.e030034.8","unstructured":"Centre for Remote Health . CARPA standard treatment manual: A clinic manual for primary health care practitioners in remote and Indigenous health services in central and northern Australia. 7th ed. Alice Springs: Centre for Remote Health, 2017."},{"key":"2025121411224285000_10.1.e030034.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.5034"},{"key":"2025121411224285000_10.1.e030034.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160046","article-title":"Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies","volume":"11","author":"Garc\u00eda Rodr\u00edguez","year":"2016","journal-title":"PLoS One"},{"key":"2025121411224285000_10.1.e030034.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025760"},{"key":"2025121411224285000_10.1.e030034.12","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"The Lancet"},{"key":"2025121411224285000_10.1.e030034.13","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on Disability-free survival in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121411224285000_10.1.e030034.14","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121411224285000_10.1.e030034.15","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121411224285000_10.1.e030034.16","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","year":"2009","journal-title":"The Lancet"},{"key":"2025121411224285000_10.1.e030034.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1805"},{"key":"2025121411224285000_10.1.e030034.18","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-Sppc01"},{"key":"2025121411224285000_10.1.e030034.19","unstructured":"Royal Australian College of General Practitioners . General practice management of type 2 diabetes: 2016-18. Victoria: RACGP, 2016."},{"key":"2025121411224285000_10.1.e030034.20","doi-asserted-by":"crossref","unstructured":"Arnett DK , Blumenthal RS , Albert MA , et al . ACC\/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol 2019;2019.","DOI":"10.1001\/jamacardio.2019.2604"},{"key":"2025121411224285000_10.1.e030034.21","unstructured":"Foley M , Zhao Y , Condon J . Demographic data quality assessment for Northern Territory public hospitals. 2011: Health Gains Planning, Department of Health 2012."},{"key":"2025121411224285000_10.1.e030034.22","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"2025121411224285000_10.1.e030034.23","doi-asserted-by":"publisher","DOI":"10.1093\/pan\/mpr013"},{"key":"2025121411224285000_10.1.e030034.24","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"2025121411224285000_10.1.e030034.25","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu125"},{"key":"2025121411224285000_10.1.e030034.26","unstructured":"Rosenbaum PR . Observational studies. New York: Springer, 2013."},{"key":"2025121411224285000_10.1.e030034.27","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2113"},{"key":"2025121411224285000_10.1.e030034.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.01.018"},{"key":"2025121411224285000_10.1.e030034.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.02.325"},{"key":"2025121411224285000_10.1.e030034.30","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2451"},{"key":"2025121411224285000_10.1.e030034.31","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12828"},{"key":"2025121411224285000_10.1.e030034.32","doi-asserted-by":"crossref","unstructured":"Jeyaraman K , Berhane T , Hamilton M , et al . Mortality in patients with diabetic foot ulcer: a retrospective study of 513 cases from a single centre in the Northern Territory of Australia. BMC Endocr Disord 2019;19.doi:10.1186\/s12902-018-0327-2","DOI":"10.1186\/s12902-018-0327-2"},{"key":"2025121411224285000_10.1.e030034.33","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2112"},{"key":"2025121411224285000_10.1.e030034.34","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-4-22","article-title":"Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications","volume":"4","author":"Hern\u00e1ndez-D\u00edaz","year":"2006","journal-title":"BMC Med"},{"key":"2025121411224285000_10.1.e030034.35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-Dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice","volume":"357","author":"Roncaglioni","year":"2001","journal-title":"The Lancet"},{"key":"2025121411224285000_10.1.e030034.36","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/dme.13133","article-title":"Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials","volume":"34","author":"Kunutsor","year":"2017","journal-title":"Diabet. Med."},{"key":"2025121411224285000_10.1.e030034.37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1755-5922.2011.00291.x","article-title":"Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? simulation data from the reach registry Australian cohort","volume":"31","author":"Ademi","year":"2013","journal-title":"Cardiovasc Ther"},{"key":"2025121411224285000_10.1.e030034.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804988"},{"key":"2025121411224285000_10.1.e030034.39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5694\/j.1326-5377.2009.tb02826.x","article-title":"Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?","volume":"191","author":"Davis","year":"2009","journal-title":"Med J Aust"},{"key":"2025121411224285000_10.1.e030034.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"2025121411224285000_10.1.e030034.41","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.12.3264"},{"key":"2025121411224285000_10.1.e030034.42","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0577"},{"key":"2025121411224285000_10.1.e030034.43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5694\/mja16.01138","article-title":"Progress in closing the gap in life expectancy at birth for Aboriginal people in the Northern Territory, 1967\u20132012","volume":"207","author":"Georges","year":"2017","journal-title":"Medical Journal of Australia"},{"key":"2025121411224285000_10.1.e030034.44","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6963-11-24","article-title":"Early identification and preventive care for elevated cardiovascular disease risk within a remote Australian Aboriginal primary health care service","volume":"11","author":"Burgess","year":"2011","journal-title":"BMC Health Serv Res"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-030034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:22:51Z","timestamp":1765740171000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-030034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,2]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1136\/bmjopen-2019-030034"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-030034","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2019-030034.supp1","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}